MedTrace Logo

Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

NCT02498860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2021-08-06

No results posted yet for this study

Summary

Two-Year Disease Free Survival Rate of Stage IB\~IIIA adenocarcinoma after Adjuvant Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be recruited for 12 months, and followed for two years, thus the duration of study will be 36 months.

Conditions

  • Adenocarcinoma
  • Lung Neoplasm

Interventions

DRUG

Pemebit

500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles

DRUG

Cisplatin

75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles

Sponsors & Collaborators

  • Kosin University Gospel Hospital

    collaborator OTHER

  • Korea University Guro Hospital

    collaborator OTHER

  • Severance Hospital

    collaborator OTHER

  • Chungnam National University Hospital

    collaborator OTHER

  • Kyungpook National University Hospital

    collaborator OTHER

  • Pusan National University Hospital

    collaborator OTHER

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • Young-Chul Kim, MD, PhD · Chonnam National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2018-02-06
Completion
2021-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02498860 on ClinicalTrials.gov